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ABSTRACT
Objectives: Few studies have investigated the
injection patterns for botulinum toxin type A for the
treatment of heterogeneous forms of cervical dystonia
(CD). This large, prospective, open-label, multicentre
study aimed to evaluate the effectiveness and safety of
500 U botulinum toxin A for the initial treatment
according to a standardised algorithm of the two most
frequent forms of CD, predominantly torticollis and
laterocollis.
Design: Patients (aged $18 years) with CD not
previously treated with botulinum neurotoxin therapy
were given one treatment with 500 U Dysport,
according to a deﬁned intramuscular injection
algorithm based on clinical assessment of direction of
head deviation, occurrence of shoulder elevation,
occurrence of tremor (all evaluated using the Tsui
rating scale) and hypertrophy of the
sternocleidomastoid muscle.
Results: In this study, 516 patients were enrolled, the
majority of whom (95.0%) completed treatment. Most
patients had torticollis (78.1%). At week 4, mean Tsui
scores had signiﬁcantly decreased by  4.01,  3.76
and  4.09 points in the total, torticollis and laterocollis
populations, respectively. Symptom improvement was
equally effective between groups. Tsui scores
remained signiﬁcantly below baseline at week 12 in
both groups. Treatment was well tolerated; the most
frequent adverse events were muscular weakness
(13.8%), dysphagia (9.9%) and neck pain (6.6%).
Conclusions: Dysport 500 U is effective and well
tolerated for the de novo management of a range of
heterogeneous forms of CD, when using
a standardised regimen that allows tailored dosing
based on individual symptom assessment.
Clinical trials information: (NCT00447772;
clinicaltrials.gov)
INTRODUCTION
Idiopathic cervical dystonia (CD) is the most
frequent form of focal dystonia and is char-
acterised by sustained involuntary muscle
contraction and/or twitching of cervical
musculature, resulting in head and neck
movements as well as various undesired head
positions.
1 Depending on the direction of
head movement, CD can be commonly clas-
siﬁed as torticollis (turning of the head),
laterocollis (head and neck tilt), retrocollis
(head and neck extension), anterocollis
(head and neck ﬂexion) or a combination of
the above. A more detailed analysis of the
muscles that are involved in CD has recently
been performed, taking into account
whether the head or the neck is predomi-
nantly forced into abnormal positions,
2 and
this analysis may lead to new classiﬁcation
and terminology. However, this has yet to be
widely adopted, and the former classiﬁcation
is still routinely used in clinical practice.
Botulinum neurotoxin (BoNT) has a long-
standing and widespread use for the treat-
ment of CD and is recommended as the
ﬁrst-line treatment option.
3 The efﬁcacy of
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ARTICLE SUMMARY
Article focus
- Evaluation of the beneﬁts of a treatment algo-
rithm for the use of Dysport for the de novo
management of torticollis and laterocollis in
a large population of patients with cervical
dystonia (CD).
Key messages
- Dysport 500 U is effective and well tolerated for
the de novo treatment of the majority of patients
suffering from the most common forms of CD.
- The treatment algorithm proposed represents
a clinically useful treatment algorithm to individ-
ualise Dysport treatment in approximately 90%
of all CD subgroups.
Strengths and limitations of this study
- Strengths of this study include the larger patient
population treatment.
- The injection protocol proposed can be useful to
guide initial treatment in de novo patients with
CD but should not replace clinical judgement and
individual patient assessment.
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Open Access Researchbotulinum toxin A (Dysport) for the treatment of CD
has been demonstrated in multiple randomised,
placebo-controlled trials.
4e7 These studies have shown
that Dysport 500 U is an effective and well-tolerated
starting dose for the treatment of CD and provides
symptom relief for up to 3 months.
4e7 Apart from one
study speciﬁcally investigating the effects of Dysport on
torticollis,
4 the other studies have included a heteroge-
neous CD patient population with the number of injec-
tion sites and Dysport dose at each site determined based
on investigator judgement.
5e7 Careful selection of the
dose of toxin used per muscle is essential, as inappro-
priate dosing can increase the risk of adverse events such
as focal muscle weakness.
8 Therefore, an injection
protocol was predeﬁned in this study, specifying dose
and injection sites to minimise the risk of side-effects and
systematically evaluate the effectiveness and safety of this
dosing algorithm tailored to the individual heteroge-
neous subtypes of CD. As such, this large, prospective,
open-label, multicentre study aimed not only to conﬁrm
the effectiveness and safety of Dysport 500 U for the
initial treatment of the two most frequent forms of CD
(predominantly torticollis and laterocollis) but also to
evaluate the treatment algorithm used in this study
(ﬁgure 1). This algorithm may help inexperienced users
to inject Dysport effectively and safely.
METHODS
Study design and patients
This was a prospective, multicentre, open-label study
conducted in Germany and Austria to investigate the
effectiveness and safety of 500 U Dysport for the treat-
ment of heterogeneous forms of CD. As botulinum toxin
type A (BoNT-A) is regarded as a ﬁrst-line neurological
therapy for the treatment of CD, this study did not
include a placebo-control arm. The study was conducted
in accordance with the Declaration of Helsinki, taking
into account local regulatory requirements; all patients
provided written informed consent to participate.
Male and female outpatients, aged $18 years, with CD
not previously treated with BoNT therapy, were eligible
for inclusion. Exclusion criteria comprised patients with
pure anterocollis or retrocollis, pure tremor capitis, or
pure sagittal or lateral shifts, as these are rare complex
forms of CD (<10%) and may require different treat-
ment algorithms. Additional exclusion criteria included
previous treatment with botulinum toxin for any indi-
cation other than CD within the past 12 months, as well
as known antibodies to BoNT.
Study treatment and treatment algorithm
All patients received 500 U Dysport (Ipsen Biopharm,
Wrexham, UK), diluted in 2.5 ml 0.9% NaCl. Treatment
was administered by intramuscular injections according
to three predeﬁned main decision steps. The investi-
gator had to follow these steps and select (out of the
12 given injection protocols) the best suitable for the
individual patient (ﬁgure 1):
1. main type of CD (either torticollis or laterocollis
based on the Tsui score);
2. shoulder elevation ($2 Tsui score, subscore C) or
tremor (tremor, myoclonia, corresponding to Tsui
score 4, subscore D), which had to be treated as
a second component;
3. presence of hypertrophy of the sternocleidomastoid
muscle (marked vs light or no hypertrophy).
This decision cascade resulted in a corresponding
injection protocol deﬁning the dose and number of
injection points per muscle (ﬁgure 1). The injection
protocol for shoulder elevation was used when the
patient had a shoulder elevation $2 in Tsui subscore C.
The injection protocol for tremor was used when the
Figure 1 Cervical dystonia
types/subtypes and injection
protocol. One vial of Dysport
(500 U) is dissolved in 2.5 ml 0.9%
NaCl solution, the values given are
the applied units. Plus shoulder
elevation: ¼ 2 Tsui score,
subscore C; Plus tremor:
Tsui score 4, subscore D;
Sternocleidomastoid muscle
hypertrophy: yes (marked) or
none/mild (light/no) hypertrophy.
CL, contralateral to movement
direction; IL, ipsilateral to
movement direction; SCM,
sternocleidomastoid muscle.
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Dysport for treatment of cervical dystoniapatients had a tremor score of 4 in Tsui subscore D. If
the patient fulﬁlled both these criteria, it was the inves-
tigator’s decision to treat the symptoms which were the
most disabling for the patient and to use the corre-
sponding injection protocol. Electromyography (EMG)
guidance for injection was left to the discretion of the
investigator.
Assessments
The decision rules follow a careful assessment of severity
of CD symptoms using the Tsui scale
9 under stand-
ardised conditions with the patient in a relaxed seated
position. Assessment of CD symptom severity using
the Tsui total score was repeated at weeks 4 and 12
post-treatment. The primary efﬁcacy outcome was
a change from baseline to week 4 in Tsui total score after
treatment.
In addition, both investigators and patients provided
a global assessment efﬁcacy at weeks 4 and 12 post-
treatment. This was rated on a four-point scale (1¼very
good; 2¼good; 3¼moderate; 4¼insufﬁcient).
Safety assessments included incidence of AEs, neuro-
logical and physical examinations, vital signs and patient
and investigator global assessment of tolerability, rated
on a four-point scale (1¼very good; 2¼good;
3¼moderate; 4¼insufﬁcient).
Statistical analyses
An original sample size of 600 subjects, enrolled over
24 months, was planned in order to detect a one-point
between-treatment group difference on change from
baseline to week 4 in Tsui total score with 90% power.
However, this target was not reached, and as such,
recruitment was stopped at 516 patients after 39 months.
Following a data review, the primary statistical analysis
plan was regarded as exploratory, and thus no adjust-
ments for multiplicity were made. The safety population
included all patients who received study medication and
had at least one safety assessment. Effectiveness analyses
were conducted on the intention-to-treat population,
which included all patients in the safety sample who had
at least one baseline and one post-treatment Tsui total
score assessment. Additionally, conﬁrmatory analyses
using the per-protocol population (excluding major
protocol violations) were conducted.
The primary effectiveness endpoint, the mean change
in Tsui total score between baseline and week 4, was
assessed by analysis of covariance (ANCOVA), with
baseline Tsui total score as covariate and the main type
of CD as between-group factor. Analyses were conducted
for the total population and by main type of CD. The
time course of the Tsui total score improvement was
investigated by means of repeated-measures ANCOVA
models, which included the main type of CD and week of
assessment as the main effects and type of CD and week
of assessment as covariates. The mean percentage
improvement in Tsui total scores at weeks 4 and 12 was
also evaluated for each main type of CD; this analysis was
speciﬁed post-hoc in order to facilitate comparison of
the results with other studies. Safety data were analysed
descriptively.
RESULTS
Patient disposition and demographics
A total of 516 patients were enrolled in this study at 81
study sites in Germany and Austria. The safety sample
consisted of 515 patients; one patient received treatment
but was excluded from the safety analysis, as no safety
data were available. Patient disposition is shown in
ﬁgure 2. Four hundred and eighty-nine patients (95.0%)
included in the safety sample completed the study.
Patient demographics and baseline characteristics are
shown in table 1. The majority of patients had torticollis
(n¼402; 78.1%); 112 patients (21.7%) had laterocollis;
the type of CD was unknown in one patient. Baseline
characteristics were similar between patients with torti-
collis and laterocollis, although the proportion of males
was higher in patients with torticollis (32.6%) compared
with patients with laterocollis (27.7%). More than half of
patients (56.5%) experienced pain associated with CD,
and 12.6% of patients had a documented additional
sagittal or lateral shift. Twelve patients (2.3%) reported
dysphagia before treatment due to head deviation
(torticollis n¼7 and laterocollis n¼5).
Treatments and dosing
All treated patients received Dysport 500 U at baseline
with the exception of three patients who received less
than 500 U (non-compliance to the injection protocol).
All injections were given without EMG guidance. The
most frequently reported concomitant medications
(>10% of patients) by therapeutic class were beta-
blocking agents (19.0%), agents acting on the
renineangiotensin system (14.4%), psychoanaleptics
(13.6%), thyroid therapy (13.0%) and analgesics
(10.1%). Concomitant medication use was similar
between CD types.
Figure 2 Patient disposition. *One patient was excluded from
the safety analysis as treatment was discontinued prematurely
due to insufﬁcient compliance. No safety data was collected for
this patient.
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Dysport for treatment of cervical dystoniaEfﬁcacy
For the primary efﬁcacy endpoint, Dysport signiﬁcantly
decreased mean Tsui total scores from baseline to week 4
( 3.83; 95% CIs  4.01 to  3.57; p<0.0001) in the total
population. Dysport also signiﬁcantly decreased Tsui
total scores from baseline to week 4 for patients with
torticollis ( 3.76; 95% CI  4.02 to  3.51; p<0.0001)
and patients with laterocollis ( 4.09; 95% CI  4.58 to
 3.59; p<0.0001), corresponding to a percentage
improvement of 43.7636.4% and 46.5628.3%, respec-
tively (total population: 44.3634.8%). The mean treat-
ment difference between the torticollis and laterocollis
groups was not statistically signiﬁcant ( 0.32; 95% CI
 0.88 to 0.23; p¼0.255), indicating that both forms of
CD equally improved at week 4.
Signiﬁcant improvements in Tsui total scores were
sustained to week 12 for both CD types (ﬁgure 3),
corresponding to similar percentage improvements in
patients with torticollis (23.6644.6%) and laterocollis
(27.0633.0%) (total population 24.3642.4%).
Analysis of data using the per-protocol population
(n¼490) conﬁrmed ﬁndings from the intention-to-treat
analysis (n¼503).
In analyses of the total population, the mean changes
in Tsui subscale scores from baseline to week 4 were
statistically signiﬁcant for all Tsui subscores: amplitude of
rotation, deﬂection (tilt) and ante-/retrocollis, subscore
A:  1.4; 95% CI  1.5 to  1.3; duration of movement,
subscore B:  0.3; 95% CI  0.4 to  0.3; severity and
duration of shoulder elevation, subscore C:  0.4; 95%
CI  0.5 to  0.3; and tremor, subscore D:  0.6; 95% CI
 0.7 to  0.5). The percentage improvement between
the mean Tsui score at baseline and V2 was greatest for
severity of tremor (45%, subscore D) and least for
duration of movement (22%, subscore B). The
percentage improvement in mean values between base-
line and V2 was 40% each for subscores A (amplitude)
and C (shoulder elevation), respectively.
Table 1 Baseline patient demographics: safety sample
Parameter Torticollis (n[402) Laterocollis (n[112) Total* (n[515)
Gender, n (%) male 131 (32.6) 31 (27.7) 162 (31.5)
Age, years
Mean (SD) 51.9 (12.7) 51.9 (12.8) 51.9 (12.7)
Range 19e83 19e87 19e87
Height, cm (mean (SD))y 169.1 (8.6) 168.4 (8.7) 169.0 (8.6)
Weight, kg (mean (SD))y 73.2 (15.4) 70.7 (12.1) 72.6 (14.7)
BMI, kg/m
2 (mean (SD))y 25.5 (4.6) 24.9 (3.6) 25.3 (4.4)
Race, n (%)
Caucasian 398 (99.0) 112 (100.0) 511 (99.2)
Asian 1 (0.2) 0 (0.0) 1 (0.2)
Oriental 3 (0.7) 0 (0.0) 3 (0.6)
Additional CD symptoms, n (%)
Pain (p¼0.0676z) 219 (54.5) 72 (64.3) 291 (56.5)
Shift (sagittal or lateral, p¼0.0011z) 40 (10.0) 25 (22.3) 65 (12.6)
Dysphagia (p¼0.1467z) 7 (1.7) 5 (4.5) 12 (2.3)
Other 12 (3.0) 1 (0.9) 13 (2.5)
Subtypes of CD, n (%)x
Without tremor/shoulder elevation (p¼0.0006z) 131 (32.6) 18 (16.1) 149 (29.0)
With shoulder elevation (p¼0.0024z) 126 (31.3) 53 (47.3) 179 (34.8)
With tremor (p¼0.9120z) 145 (36.1) 41 (36.6) 186 (36.2)
Baseline total Tsui score (patient in sitting position),
mean (SD)x
8.4 (3.5) 8.2 (3.3) 8.4 (3.5)
*Includes one patient in whom the main type of cervical dystonia (CD) was unknown.
yTorticollis n¼399; laterocollis n¼111; total n¼510.
zFisher exact test for torticollis versus laterocollis, two-sided.
xTotal population n¼514, main type of CD was not known in one patient.
Figure 3 Mean Tsui total scores at baseline, week 4 and
week 12 in the main CD subtypes and the total population (ITT
population). *p<0.0001 vs baseline. The reduction of the Tsui
total score was highly signiﬁcant both at week 4 and 12
(p<0.0001) and, as is evident from the parallel lines, nearly
identical in the torticollis and laterocollis patient groups. CD,
cervical dystonia; ITT, intention-to-treat.
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Dysport for treatment of cervical dystoniaThe efﬁcacy of study medication in the total popula-
tion was rated as ‘very good’ or ‘good’ by 70.0% of
investigators (67.2% torticollis, 80.2% laterocollis) and
60.8% of patients (59.9% torticollis, 64.1% laterocollis)
at week 4. At week 12, efﬁcacy was rated as ‘very good’ or
‘good’ by 72.0% of investigators (70.4% torticollis,
77.9% laterocollis) and 64.9% of patients (63.8%
torticollis, 69.3% laterocollis).
Safety and tolerability
At least one AE was experienced by 41.4% of patients, of
which 30.1% were considered to be related to study
medication. The most frequent AEs (>5% of patients)
were muscular weakness (13.8%), dysphagia (9.9%) and
neck pain (6.6%); no signiﬁcant difference in the rates
of these AEs was seen between patients with torticollis
and laterocollis, except for severe muscular weakness
(table 2). Most AEs were mild to moderate in severity
(89.7%); only 53 patients (10.3%) experienced severe
AEs. A summary of safety and tolerability by main type of
CD is shown in table 2. Overall, AEs of muscular weak-
ness, dysphagia and neck pain were rated as severe in 17
(3.3%), three (0.6%) and 13 (2.5%) patients, respec-
tively (table 2). One patient experienced severe
dysphagia, severe muscular weakness and severe neck
pain simultaneously, and ﬁve patients experienced both
severe muscular weakness and severe neck pain. Nearly
all cases of severe muscular weakness (15 of 17 patients;
88.2%) and all cases of severe dysphagia (three patients)
resolved without the requirement for intervention. Of
the two patients with severe muscle weakness that were
not classed as resolved, no information was available for
one patient, and one patient had to wear a cervical collar
temporarily. Of the patients with severe neck pain
(n¼13), six (46.2%) had pain that was self-limiting and
did not require intervention, while the other seven
(53.8%) required intervention.
Eleven patients (2.1%) experienced serious AEs
(SAEs), although only two patients experienced serious
AEs that were considered possibly related to study
medication. One patient with torticollis experienced
a convulsive syncope together with bradycardia imme-
diately after injection; these symptoms resolved without
intervention after several hours, and an EEG revealed no
pathological ﬁndings. The attending physician assessed
the events as probably being an injection-related, vagal
reaction. One patient with laterocollis experienced
muscle weakness of the head and depression: these
symptoms developed 2 days post-treatment, and the
patient was hospitalised 11 days post-treatment and
treated with antidepressant medication. The patient
recovered from both events within 3 weeks.
There were no relevant or unexpected observations in
the physical and neurological examination or changes in
vital signs with Dysport treatment. Tolerability of study
medication, as assessed by investigators and patients, is
summarised in table 2.
DISCUSSION
This study is the largest prospectively designed study
conducted to date in de novo patients with CD, as well as
one of the largest studies conducted in patients with CD
in general. The results of this study, conducted at
multiple centres in Germany and Austria, demonstrate
that a single dose of Dysport 500 U can be used effec-
tively for the management of the most common forms of
Table 2 Safety and tolerability
Torticollis (n[402) Laterocollis (n[112) Total* (n[515)
Summary of AEs, n (%)
Patients with AEs 167 (41.5) 46 (41.1) 213 (41.4)
Patients with causally related AE 121 (30.1) 34 (30.4) 155 (30.1)
Patients with at least one severe AE 35 (8.7) 18 (16.1) 53 (10.3)
Patients with SAE 8 (2.0) 3 (2.7) 11 (2.1)
Patients with causally related SAE 1 (0.2) 1 (0.9) 2 (0.4)
AEs in >5% of patients in total population, n (%)
Muscular weakness (p¼0.0618)y 49 (12.2) 22 (19.6) 71 (13.8)
Severe (p¼0.0008)y 7 (1.7) 10 (8.9) 17 (3.3)
Dysphagia (p¼0.8582)y 41 (10.2) 10 (8.9) 51 (9.9)
Severe, n (%) 3 (0.7) 0 (0.0) 3 (0.6)
Neck pain (p¼0.8300)y 26 (6.5) 8 (7.1) 34 (6.6)
Severe, n (%) 9 (2.2) 4 (3.6) 13 (2.5)
Global assessment of tolerability
Percentage investigators rating tolerability as ‘good’ or ‘very good’
Week 4 87.8 82.6 86.7
Week 12 89.2 87.9 88.8
Percentage patients rating tolerability as ‘good’ or ‘very good’
Week 4 82.5 72.5 80.3
Week 12 85.7 84.1 85.4
*Includes one patient in whom the main type of CD was unknown.
yFisher exact test for torticollis versus laterocollis, two-sided.
AE, adverse event; SAE, serious adverse event.
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Dysport for treatment of cervical dystoniaCD (predominantly torticollis and laterocollis), when
being injected according to a standardised algorithm
that allows tailored dosing based on individual symptom
assessment. Dysport treatment resulted in a clinically
and statistically signiﬁcant improvement in symptoms of
CD at week 4, as assessed by Tsui total scores, and the
magnitude of improvement was comparable between
torticollis and laterocollis patients. Furthermore, in both
groups, the beneﬁt of Dysport treatment was maintained
to week 12.
The present results agree with previous studies that
demonstrated the effectiveness of 500 U Dysport for the
treatment of CD
4e7 and expand on these ﬁndings to
demonstrate the comparable effectiveness of Dysport in
the two main subtypes of CD. Dysport treatment in this
study resulted in a greater than 40% improvement in CD
symptoms at week 4 in all CD types, as measured by
improvement in Tsui scores. This compares well with the
percentage improvement in Tsui scores at week 4 in
patients treated with Dysport in a double-blind placebo
controlled study (Dysport 41% vs placebo 17%;
p¼0.002).
7
Improvements in symptoms were conﬁrmed by inves-
tigator and patient global assessment of symptoms
without distinct (signiﬁcant) group differences. Of note,
investigator and patient ratings varied most in
the laterocollis group at week 4, which could probably
be explained by the higher rate of severe muscular
weakness reported in these patients.
The treatment protocol used in this study represents
a clinically useful treatment algorithm to individualise
treatment in approximately 90% of all CD subgroups,
that is, torticollis and laterocollis, both with and without
shoulder elevation or tremor, also accounting for
hypertrophy of the sternocleidomastoid muscle. Inde-
pendently, it is still essential for treating physicians to
understand the biomechanical effects of the muscles
involved in the primary movements of the head in order
to optimise treatment when using this algorithm. The
majority of patients with CD may be treated by the
present investigated, standardised injection protocol.
However, this protocol may not be suitable for patients
with rare, more complex forms of CD. Thus, injection
algorithms may facilitate effective dosing of BoNT-A, as
excess dosing into muscles not involved in CD symptoms
may not improve efﬁcacy but rather increase the risk of
AEs. The ﬁndings of this study support the use of one
vial of 500 U Dysport as an appropriate starting dose for
patients with CD
4e7 and comply with ﬁndings of a recent
long-term follow-up of Dysport in CD, suggesting that
the majority of patients can beneﬁt from this dose over
the longer term, given a careful injection technique.
10
The algorithm presented allows the optimal distribution
of one 500 U vial of Dysport based on the patient’s
clinical picture, assessed by the Tsui score, and is prac-
ticable in a normal clinical setting.
Dysport was well tolerated for the treatment of CD in
this study; most AEs were mild to moderate in severity,
and the majority of patients and investigators rated
treatment tolerability as very good/good, regardless of
torticollis or laterocollis. Interestingly, and as seen in the
efﬁcacy ratings, investigator and patient ratings of toler-
ability varied most in the laterocollis group at week 4. It
is possible that the statistically signiﬁcant difference in
severe muscular weakness between torticollis and later-
ocollis patients explains why laterocollis patients rated
their tolerability of study treatment lower than torticollis
patients at week 4. No new safety concerns were raised
by this study, and the most common AEs reported,
muscular weakness and dysphagia, were consistent
with the known safety proﬁle of this medication in this
indication.
11
The reported rates of muscle weakness and dysphagia
were consistent with those reported for Botox in de novo
patients,
12 although there are inherent limitations in
comparing data, assessment methods and botulinum
toxin A formulations between studies. Rates of dysphagia
and muscular weakness presented here are lower than
rates reported in previously conducted double-blind,
placebo-controlled trials with Dysport,
56probably due to
dose distribution of Dysport based on a predeﬁned
injection protocol. Speciﬁcally, with regard to dysphagia,
the majority of the BoNT-A dose in this study was
injected into the posterior part of the neck region. Thus,
the results show that the use of predeﬁned injection
protocols allowing individual symptom treatment may
have the potential to improve treatment tolerability by
providing patients with effective symptom relief while
possibly limiting AEs associated with injecting non-
involved muscles. Finally, it is important to point out that
the injection protocol may guide the initial treatment in
de novo patients with CD. However, the dose and muscle
selection of further injections should always consider the
patient’s individual symptoms in conjunction with the
initial treatment outcomes. Careful and extensive clin-
ical examination and diagnosis are essential in all
patients, especially those presenting with symptoms of
pain and dysphagia caused by head deviation.
In conclusion, Dysport 500 U is effective and well
tolerated for the de novo treatment of the majority
of patients suffering from the most common forms of
CD. Analyses of additional secondary effectiveness
outcomes collected in this study will provide further
insight into the beneﬁts of Dysport in this de novo
patient group.
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APPENDIX 1
Dysport Cervical Dystonia Study Group
Members of the Dysport Cervical Dystonia Study Group in Germany
were (in alphabetical order of study sites): H Eing (Ahaus); A Plewe
(Apolda); B Patzner (Arnsdorf); H Griese (Bad Oeyenhausen); M Pott
(Bayreuth); A Nebe, T Winter and J Wissel (Beelitz-Heilsta ¨tten);
H Woldag (Bennewitz); W Raffauf (Berlin); K Tiel-Wilck (Berlin);
AM Garcia, D Gruber, F Kempf, H Krug, E Lobsien (Berlin); S Leistner
(Berlin); A Schenkel-Ro ¨mer (Berlin); S Eue (Bernburg); M Bonse
(Bielefeld); I Nastos (Bochum); S Otto (Bochum); T Grehl and
M Tegenthoff (Bochum); M Ebke (Bremen); E Kunesch, T Probst and
M Richter (Deggendorf); A Hermann and M Wolz (Dresden); U Kahlen
and M Moll (Du ¨sseldorf); A Gru ¨ger (Eberswalde); P Feise, H W Ko ¨lmel
and L Kotthaus (Erfurt); M Haslbeck (Erlangen); A Jaspert-Grehl
(Essen); M Maschke, M Obermann and N Putzki (Essen); J Bo ¨hm
(Freiberg); C Schiel (Gießen), M Hahn (Gießen), I Reuter and
S Schmidt (Gießen); H Krumpolt (Großschweidnitz); FM Brake
(Hagen); F Hoffmann and C Wohlrab (Halle-Do ¨lau); V Becker and
T Humbert (Hamburg); B Mohammadi (Hannover), R Dengler,
K Kollewe, K Krampﬂ and S Petri (Hannover); J Osterhage (Homburg);
DM u ¨ller (Ilmenau); K Gehring (Itzehoe); G Heide and A Jentsch
(Jena); M Morgenthaler (Kaiserslautern); J Volkmann (Kiel); U Marc-
zynski and J Wo ¨hrle (Koblenz); B Wittmann (Landshut); S Peschel
(Leipzig); P Baum (Leipzig); R Schneider (Lemgo); J Hagenah
(Lu ¨beck); K-A Bohr (Lu ¨neburg); H Ba ¨zner and C Blahak (Mannheim);
J Philipps (Minden); R Althoff, J Haan and K Kessler (Mo ¨nchen-
gladbach); F Castrop, C Dresel, L Esposito, C Loer and B Haslinger
(Mu ¨nchen), AO Ceballos-Baumann, U Fietzek, M Messner and L Riedl
(Mu ¨nchen); M Ritter and P Young (Mu ¨nster); F Erbguth (Nu ¨rnberg),
R Witte (Oldenburg); M Putzer (Paderborn); H Kursawe (Potsdam);
K Stutterheim (Potsdam); J Vollmer-Haase (Recklinghausen);
R Benecke (Rostock), M Scho ¨ffel (Ru ¨dersdorf); E Fleischer (Schorn-
dorf); A Nguento (Schwedt/Oder); A Bartels (Schwerin); T Warnecke
(Seesen); H Roick (Singen); M Petrick (Teupitz); J Hahn (Weiden);
E Fucik, S Heitmann and B Zeiler (Wiesbaden); P Cordes and
J Schierenbeck (Wolfenbu ¨ttel); C Helbig, M Klein and K-U Oehler
(Wu ¨rzburg); M Beck and A Schramm (Wu ¨rzburg); G Hennen
(Wuppertal); G Reichel (Zwickau).
Members of the Dysport Cervical Dystonia Study Group in Austria
were (in alphabetical order of study sites): J Diez (Graz); P Schnider
(Grimmenstein-Hochegg); T Haydn, J Mu ¨ller and W Poewe
(Innsbruck); RJ Resch and R Sommer (Linz).
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